Indivior Pharmaceuticals, Inc.
NASDAQINDV delivered a sharp Q1 2026 earnings beat today, setting up an unusually charged week-end for a stock that shorts have been quietly building into. Q1 adjusted EPS came in at $0.96, versus a Street estimate of $0.66. Sales hit $317 million against a $272.8 million consensus — a beat of more than 16%. Management followed that with a full-year guidance raise, lifting the sales…
Snapshot as of 7 May 2026
INDV delivered a sharp Q1 2026 earnings beat today, setting up an unusually charged week-end for a stock that shorts have been quietly building into. Q1 adjusted EPS came in at $0.96, versus a Street estimate of $0.66.…
INDV enters its April 30 earnings release with momentum firmly behind it — but short sellers are quietly building positions even as the stock climbs. The price action tells an optimistic story. INDV has gained 18% over…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for INDV — free to start on ORTEX.
Sign up for free →Open INDV on ORTEX